1443-42-1

Basic information

• Product Name: (4-METHYLPYRIDIN-3-YL)METHYLAMINE
• Synonyms: RARECHEM AL BW 2467;(4-METHYLPYRIDIN-3-YL)METHYLAMINE;4-Methyl-3-PyridineMethanaMine;3-AMinoMethyl-4-Methylpyridine
• CAS NO: 1443-42-1
• Molecular Formula: C₇H₁₀N₂
• Molecular Weight: 122.17
• Product Categories: Aminomethyl's;Pyridines
• Mol File: 1443-42-1.mol

Chemical Properties

• Boiling Point: 242.8°C at 760 mmHg
• Flash Point: 121.3°C
• Appearance: /
• Density: 1.027g/cm³
• Vapor Pressure: 0.0332mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.39±0.29(Predicted)
• CAS DataBase Reference: (4-METHYLPYRIDIN-3-YL)METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHYLPYRIDIN-3-YL)METHYLAMINE(1443-42-1)
• EPA Substance Registry System: (4-METHYLPYRIDIN-3-YL)METHYLAMINE(1443-42-1)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-38-41
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 1443-42-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
(4-METHYLPYRIDIN-3-YL)METHYLAMINE is used as a building block for the synthesis of various pharmaceutical and agrochemical products due to its ability to form stable complexes with transition metals, enhancing the efficacy and properties of the final products.
Used in Medicinal Chemistry and Drug Discovery:
(4-METHYLPYRIDIN-3-YL)METHYLAMINE is used as a ligand in the coordination of transition metals for medicinal chemistry and drug discovery, contributing to the development of new therapeutic agents with improved pharmacological profiles.
Used in the Production of Organic Intermediates:
(4-METHYLPYRIDIN-3-YL)METHYLAMINE is used as a key component in the production of various organic intermediates, which are essential precursors in the synthesis of a wide range of chemical compounds.
Used in the Synthesis of Heterocyclic Compounds:
(4-METHYLPYRIDIN-3-YL)METHYLAMINE is used as a starting material in the synthesis of heterocyclic compounds, which are important in various fields such as pharmaceuticals, materials science, and agrochemicals, due to their diverse chemical and biological properties.

InChI:InChI=1/C7H10N2/c1-6-2-3-9-5-7(6)4-8/h2-3,5H,4,8H2,1H3

Upstream product

• 7250-52-4 4-methyl-3-pyridinecarboxamide 
• 3222-50-2 4-methylnicotinic acid 
• 5444-01-9 3-cyano-4-methylpyridine 

Downstream Products

• 1439358-29-8 C₁₄H₁₄ClN₃O₃S 
• 1439357-96-6 C₂₀H₁₉N₃O₃S 

Relevant articles and documents

Pyridine methylamine compound and preparation method thereof

The invention provides a pyridine methylamine compound and a preparation method thereof. The preparation method comprises the steps that tetrahydrofuran and sodium borohydride are sequentially added into a cyanopyridine compound, then an iodine-containing tetrahydrofuran solution is dropwise added, a reaction is conducted at the temperature of 20-30 DEG C, and after dropwise adding is completed, stirring is carried out continuously; after the reaction is finished, methanol is added for refluxing, extracting and spin-drying are carried out to obtain the pyridine methylamine compound; wherein a functional group in the cyanopyridine compound is selected from chlorine, bromine, methyl, ethyl, amino or hydrogen; according to the preparation method, high-temperature and high-pressure special equipment does not need to be used, so that the preparation method is relatively safe, and dangerous accidents such as explosion and fire disasters are avoided; besides, the preparation method is relatively environment-friendly, recycling treatment of hazardous waste (used Raney nickel) is not involved, the economic benefit is relatively high, borane generated by the synthesis method is converted into boric acid esters in the post-treatment process, the treatment cost is low, and the harm to the environment is much small.

HETEROCYCLIC COMPOUND AND USE THEREOF

Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):

7-Substituted Purine Derivatives for Immunosuppression

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III:

7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula (III).

PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. Thesd compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).